Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*).

Yang W, Chen L, Ji Q, Liu X, Ma J, Tandon N, Bhattacharyya A, Kumar A, Kim KW, Yoon KH, Bech OM, Zychma M

Diabetes, obesity & metabolism1 Jan 2011Cited by 78 (Europe PMC)

PMID21114607DOI10.1111/j.1463-1326.2010.01323.xPepBankPUB-21114607

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Asian adults with type 2 diabetes on metformin, HbA1c was significantly reduced from baseline in all groups, including the liraglutide groups.
In plain wordsIn Asian adults with type 2 diabetes, HbA1c fell from baseline in every group, including those taking liraglutide.
Peptide
Liraglutide
Outcome
DecreaseHbA1c reduction from baseline
Study
n = 929
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6, 1.2 or 1.8 mg once daily · 16 weeksAs given in this study (human).
Source sentences
Summary
HbA₁(c) was significantly reduced in all groups compared with baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
A 16-week, randomized, double-blind, double-dummy, four-arm, active control trial was carried out.
Summary · context
In total, 929 subjects with type 2 diabetes with a mean (±s.d.) age of 53.3 ± 9.5 years, HbA₁(c) of 8.6 ± 1.0% and body weight of 68.1 ± 11.7 kg were randomized (liraglutide 0.6, 1.2 or 1.8 mg once daily or glimepiride 4 mg once daily all in combination with metformin: 1 : 1 : 1 : 1).
Report a problemFND-2111460701
02HumanRandomized controlled trialSafety outcome
In Asian adults with type 2 diabetes on metformin, no major hypoglycaemia occurred in the liraglutide groups, while two subjects on glimepiride reported it.
In plain wordsIn Asian adults with type 2 diabetes, no one on liraglutide had severe low blood sugar, while two people on glimepiride did.
Peptide
Liraglutide
Outcome
Direction not reportedMajor hypoglycaemia
Study
n = 929
Comparator
Glimepiride 4 mg once daily
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.6, 1.2 or 1.8 mg once daily · 16 weeksAs given in this study (human).
Source sentences
Summary
Two subjects in the glimepiride group reported major hypoglycaemia while none in the liraglutide groups.
2 context sentences(design, population, supporting numbers)
Summary · context
A 16-week, randomized, double-blind, double-dummy, four-arm, active control trial was carried out.
Summary · context
In total, 929 subjects with type 2 diabetes with a mean (±s.d.) age of 53.3 ± 9.5 years, HbA₁(c) of 8.6 ± 1.0% and body weight of 68.1 ± 11.7 kg were randomized (liraglutide 0.6, 1.2 or 1.8 mg once daily or glimepiride 4 mg once daily all in combination with metformin: 1 : 1 : 1 : 1).
Report a problemFND-2111460708
03HumanRandomized controlled trialSafety outcome
In Asian adults with type 2 diabetes on metformin, liraglutide was associated with about 10-fold lower incidence of minor hypoglycaemia than glimepiride.
In plain wordsIn Asian adults with type 2 diabetes, mild low blood sugar was about 10 times less frequent with liraglutide than with glimepiride.
Peptide
Liraglutide
Outcome
DecreaseMinor hypoglycaemia
Study
n = 929
Comparator
Glimepiride 4 mg once daily
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.6, 1.2 or 1.8 mg once daily · 16 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide was associated with about 10-fold lower incidence of minor hypoglycaemia than glimepiride.
2 context sentences(design, population, supporting numbers)
Summary · context
A 16-week, randomized, double-blind, double-dummy, four-arm, active control trial was carried out.
Summary · context
In total, 929 subjects with type 2 diabetes with a mean (±s.d.) age of 53.3 ± 9.5 years, HbA₁(c) of 8.6 ± 1.0% and body weight of 68.1 ± 11.7 kg were randomized (liraglutide 0.6, 1.2 or 1.8 mg once daily or glimepiride 4 mg once daily all in combination with metformin: 1 : 1 : 1 : 1).
Report a problemFND-2111460709
04HumanRandomized controlled trialEfficacy outcome
In Asian adults with type 2 diabetes on metformin, liraglutide 1.2 mg was non-inferior to glimepiride for HbA1c reduction (1.36 vs 1.39 percentage points).
In plain wordsIn Asian adults with type 2 diabetes, liraglutide 1.2 mg lowered HbA1c about as much as glimepiride.
Peptide
Liraglutide
Outcome
No significant changeHbA1c reduction, liraglutide 1.2 mg versus glimepiride
Study
n: not reported in source
Comparator
Glimepiride 4 mg once daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg once daily · 16 weeksAs given in this study (human).
Measurements
HbA1c reduction
1.36 % points
liraglutide 1.2 mg
HbA1c reduction
1.39 % points
glimepiride
Source sentences
Summary
Treatment with liraglutide 1.2 and 1.8 mg was non-inferior to glimepiride (mean HbA₁(c) reduction: 1.36% points, 1.45% points and 1.39% points, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
A 16-week, randomized, double-blind, double-dummy, four-arm, active control trial was carried out.
Summary · context
In total, 929 subjects with type 2 diabetes with a mean (±s.d.) age of 53.3 ± 9.5 years, HbA₁(c) of 8.6 ± 1.0% and body weight of 68.1 ± 11.7 kg were randomized (liraglutide 0.6, 1.2 or 1.8 mg once daily or glimepiride 4 mg once daily all in combination with metformin: 1 : 1 : 1 : 1).
Report a problemFND-2111460702
05HumanRandomized controlled trialEfficacy outcome
In Asian adults with type 2 diabetes on metformin, liraglutide 1.8 mg was non-inferior to glimepiride for HbA1c reduction (1.45 vs 1.39 percentage points).
In plain wordsIn Asian adults with type 2 diabetes, liraglutide 1.8 mg lowered HbA1c about as much as glimepiride.
Peptide
Liraglutide
Outcome
No significant changeHbA1c reduction, liraglutide 1.8 mg versus glimepiride
Study
n: not reported in source
Comparator
Glimepiride 4 mg once daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg once daily · 16 weeksAs given in this study (human).
Measurements
HbA1c reduction
1.45 % points
liraglutide 1.8 mg
HbA1c reduction
1.39 % points
glimepiride
Source sentences
Summary
Treatment with liraglutide 1.2 and 1.8 mg was non-inferior to glimepiride (mean HbA₁(c) reduction: 1.36% points, 1.45% points and 1.39% points, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
A 16-week, randomized, double-blind, double-dummy, four-arm, active control trial was carried out.
Summary · context
In total, 929 subjects with type 2 diabetes with a mean (±s.d.) age of 53.3 ± 9.5 years, HbA₁(c) of 8.6 ± 1.0% and body weight of 68.1 ± 11.7 kg were randomized (liraglutide 0.6, 1.2 or 1.8 mg once daily or glimepiride 4 mg once daily all in combination with metformin: 1 : 1 : 1 : 1).
Report a problemFND-2111460703
06HumanRandomized controlled trialEfficacy outcome
In Asian adults with type 2 diabetes on metformin, the proportion reaching HbA1c below 7% did not differ between liraglutide 1.2 or 1.8 mg and glimepiride.
In plain wordsIn Asian adults with type 2 diabetes, as many people reached the HbA1c target with liraglutide as with glimepiride.
Peptide
Liraglutide
Outcome
No significant changeProportion reaching ADA HbA1c target <7%
Study
n: not reported in source
Comparator
Glimepiride 4 mg once daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 and 1.8 mg once daily · 16 weeksAs given in this study (human).
Source sentences
Summary
No significant difference was shown in the percentage of subjects reaching American Diabetes Association HbA₁(c) target <7% or American Association of Clinical Endocrinologists target ≤6.5% between liraglutide 1.2 and 1.8 mg and glimepiride.
2 context sentences(design, population, supporting numbers)
Summary · context
A 16-week, randomized, double-blind, double-dummy, four-arm, active control trial was carried out.
Summary · context
In total, 929 subjects with type 2 diabetes with a mean (±s.d.) age of 53.3 ± 9.5 years, HbA₁(c) of 8.6 ± 1.0% and body weight of 68.1 ± 11.7 kg were randomized (liraglutide 0.6, 1.2 or 1.8 mg once daily or glimepiride 4 mg once daily all in combination with metformin: 1 : 1 : 1 : 1).
Report a problemFND-2111460704
07HumanRandomized controlled trialEfficacy outcome
In Asian adults with type 2 diabetes on metformin, the proportion reaching HbA1c of 6.5% or lower did not differ between liraglutide 1.2 or 1.8 mg and glimepiride.
In plain wordsIn Asian adults with type 2 diabetes, as many people reached the stricter HbA1c target with liraglutide as with glimepiride.
Peptide
Liraglutide
Outcome
No significant changeProportion reaching AACE HbA1c target 6.5% or lower
Study
n: not reported in source
Comparator
Glimepiride 4 mg once daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 and 1.8 mg once daily · 16 weeksAs given in this study (human).
Source sentences
Summary
No significant difference was shown in the percentage of subjects reaching American Diabetes Association HbA₁(c) target <7% or American Association of Clinical Endocrinologists target ≤6.5% between liraglutide 1.2 and 1.8 mg and glimepiride.
2 context sentences(design, population, supporting numbers)
Summary · context
A 16-week, randomized, double-blind, double-dummy, four-arm, active control trial was carried out.
Summary · context
In total, 929 subjects with type 2 diabetes with a mean (±s.d.) age of 53.3 ± 9.5 years, HbA₁(c) of 8.6 ± 1.0% and body weight of 68.1 ± 11.7 kg were randomized (liraglutide 0.6, 1.2 or 1.8 mg once daily or glimepiride 4 mg once daily all in combination with metformin: 1 : 1 : 1 : 1).
Report a problemFND-2111460705
08HumanRandomized controlled trialEfficacy outcome
In Asian adults with type 2 diabetes on metformin, liraglutide reduced mean weight by 1.8-2.4 kg, compared with a 0.1 kg gain with glimepiride.
In plain wordsIn Asian adults with type 2 diabetes, weight fell with liraglutide but rose slightly with glimepiride.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n: not reported in source
Comparator
Glimepiride 4 mg once daily
Outcome group
Body weight · Metabolic and weight
Studied dose
0.6, 1.2 or 1.8 mg once daily · 16 weeksAs given in this study (human).
Measurements
Mean weight reduction
1.8 to 2.4 kg
liraglutide
Mean weight gain
0.1 kg
glimepiride
Source sentences
Summary
Liraglutide was associated with a 1.8-2.4 kg mean weight reduction, compared with a 0.1 kg mean weight gain with glimepiride.
2 context sentences(design, population, supporting numbers)
Summary · context
A 16-week, randomized, double-blind, double-dummy, four-arm, active control trial was carried out.
Summary · context
In total, 929 subjects with type 2 diabetes with a mean (±s.d.) age of 53.3 ± 9.5 years, HbA₁(c) of 8.6 ± 1.0% and body weight of 68.1 ± 11.7 kg were randomized (liraglutide 0.6, 1.2 or 1.8 mg once daily or glimepiride 4 mg once daily all in combination with metformin: 1 : 1 : 1 : 1).
Report a problemFND-2111460706
09HumanRandomized controlled trialEfficacy outcome
In Asian adults with type 2 diabetes on metformin, liraglutide reduced systolic blood pressure significantly more than glimepiride.
In plain wordsIn Asian adults with type 2 diabetes, liraglutide lowered systolic blood pressure more than glimepiride.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure
Study
n: not reported in source
Comparator
Glimepiride 4 mg once daily
Outcome group
Blood pressure · Cardiovascular
Studied dose
0.6, 1.2 or 1.8 mg once daily · 16 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide led to a significantly greater reduction in systolic blood pressure (SBP) compared with glimepiride.
2 context sentences(design, population, supporting numbers)
Summary · context
A 16-week, randomized, double-blind, double-dummy, four-arm, active control trial was carried out.
Summary · context
In total, 929 subjects with type 2 diabetes with a mean (±s.d.) age of 53.3 ± 9.5 years, HbA₁(c) of 8.6 ± 1.0% and body weight of 68.1 ± 11.7 kg were randomized (liraglutide 0.6, 1.2 or 1.8 mg once daily or glimepiride 4 mg once daily all in combination with metformin: 1 : 1 : 1 : 1).
Report a problemFND-2111460707
10HumanRandomized controlled trialSafety outcome
In Asian adults with type 2 diabetes on metformin, gastrointestinal disorders were the most common adverse events with liraglutide, but were transient and led to few withdrawals.
In plain wordsIn Asian adults with type 2 diabetes, stomach and gut side effects were most common with liraglutide but were short-lived and rarely made people stop.
Peptide
Liraglutide
Outcome
Direction not reportedGastrointestinal adverse events
Study
n: not reported in source
Comparator
Glimepiride 4 mg once daily
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.6, 1.2 or 1.8 mg once daily · 16 weeksAs given in this study (human).
Source sentences
Summary
Gastrointestinal disorders were the most common adverse events (AEs) for liraglutide, but were transient and resulted in few withdrawals.
2 context sentences(design, population, supporting numbers)
Summary · context
A 16-week, randomized, double-blind, double-dummy, four-arm, active control trial was carried out.
Summary · context
In total, 929 subjects with type 2 diabetes with a mean (±s.d.) age of 53.3 ± 9.5 years, HbA₁(c) of 8.6 ± 1.0% and body weight of 68.1 ± 11.7 kg were randomized (liraglutide 0.6, 1.2 or 1.8 mg once daily or glimepiride 4 mg once daily all in combination with metformin: 1 : 1 : 1 : 1).
Report a problemFND-2111460710
11HumanRandomized controlled trialSafety outcome
In Asian adults with type 2 diabetes on metformin, transient nausea was the most frequently reported adverse event with liraglutide.
In plain wordsIn Asian adults with type 2 diabetes, short-lived nausea was the most common side effect of liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedNausea
Study
n: not reported in source
Comparator
Glimepiride 4 mg once daily
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.6, 1.2 or 1.8 mg once daily · 16 weeksAs given in this study (human).
Source sentences
Summary
The most frequently reported AE was transient nausea.
2 context sentences(design, population, supporting numbers)
Summary · context
A 16-week, randomized, double-blind, double-dummy, four-arm, active control trial was carried out.
Summary · context
In total, 929 subjects with type 2 diabetes with a mean (±s.d.) age of 53.3 ± 9.5 years, HbA₁(c) of 8.6 ± 1.0% and body weight of 68.1 ± 11.7 kg were randomized (liraglutide 0.6, 1.2 or 1.8 mg once daily or glimepiride 4 mg once daily all in combination with metformin: 1 : 1 : 1 : 1).
Report a problemFND-2111460711

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00614120

Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 929Jan 2008 to Feb 2009

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 8 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.